{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:52:44Z","timestamp":1792623164105,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique category of juvenile arthritis in which interleukin 6 plays a major pathogenic role. This study aimed to describe the therapeutic short-term outcomes among patients with sJIA starting tocilizumab (TCZ) therapy and to identify possible predictors of treatment response.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a prospective observational study including 65 patients with sJIA meeting ILAR classification criteria with active disease despite conventional therapy that were treated by TCZ between August 2019 and October 2020 as the first-line biological therapy. Clinical and serological parameters were recorded at baseline and after 1 year of TCZ therapy.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> After 1 year, 25% of the patients achieved minimal disease activity and 35% achieved clinically inactive disease. A significant reduction of the 10-joint juvenile arthritis disease activity score and acute phase reactants was also observed. Patients with younger age (\u22647 years), shorter disease duration (\u22643 years), lower disease activity, and higher serum ferritin and systemic manifestations showed more favorable results.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Patients with sJIA showed favorable disease outcomes with TCZ treatment for 1 year, especially if the drugs were administered earlier in the disease course and in younger patients with a more pronounced inflammatory status. Our results may help to define the profile of patients with sJIA who are more likely to benefit from IL-6 blockade.<\/jats:p>","DOI":"10.3389\/fmed.2021.665028","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T04:58:18Z","timestamp":1620622698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study"],"prefix":"10.3389","volume":"8","author":[{"given":"Doaa W.","family":"Nada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkawy","family":"Moghazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah El-Sayed","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Alunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"B2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3899\/jrheum.160173","article-title":"Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas\u2014key to understanding etiology and genetic factors?","volume":"43","author":"Consolaro","year":"2016","journal-title":"J. Rheumatol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/B978-1-4160-6581-4.10014-7","article-title":"Systemic juvenile idiopathic arthritis","volume-title":"Textbook of Pediatric Rheumatology","author":"De Benedetti","year":"2011"},{"key":"B5","first-page":"1","volume-title":"Handbook of Juvenile Idiopathic Arthritis.","author":"Ravelli","year":"2015"},{"key":"B6","first-page":"1069","article-title":"Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology","volume":"27","author":"Foeldvari","year":"2000","journal-title":"J Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","article-title":"Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications","volume":"76","author":"Ombrello","year":"2017","journal-title":"Ann. Rheum. Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","article-title":"The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis","volume":"10","author":"Lin","year":"2011","journal-title":"Autoimmun. Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S109495","article-title":"Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition","volume":"8","author":"Grevich","year":"2017","journal-title":"Adolesc. Health Med. Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann. Rheum. Dis"},{"key":"B13","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis","volume":"32","author":"Kimura","year":"2005","journal-title":"J. Rheumatol"},{"key":"B14","article-title":"Clinical Commissioning Policy Statement: Biologic Therapies for the treatment of Juvenile Idiopathic Arthritis (JIA)","author":"NHS","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.40884","article-title":"American College of Rheumatology\/Arthritis Foundation Guideline for the treatment of junenile idiopathic arthritis:therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arhritis Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/acr.22259","article-title":"Childhood Arhritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis","volume":"66","author":"Ringold","year":"2014","journal-title":"Arthritis Care Res."},{"key":"B17","article-title":"CHMP post-authorisation summary of positive opinion for Actemra","year":"2011"},{"key":"B18","article-title":"TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. National Institute for Health and Care Excellence","year":"2011"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann. Rheum. Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00296-016-3595-z","article-title":"Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis","volume":"37","author":"Pacharapakornpong","year":"2017","journal-title":"Rheumatol. Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3899\/jrheum.141567","article-title":"Anakinra in systemic juvenile idiopathic arthritis: a single-center experience","volume":"42","author":"Pardeo","year":"2015","journal-title":"J. Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3899\/jrheum.180331","article-title":"Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis","volume":"46","author":"Saccomanno","year":"2019","journal-title":"J. Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant Interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.41612","article-title":"Early treatment and IL1rn snps affect response to anakinra in systemic juvenile idiopathic arthritis","volume":"72","author":"Pardeo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B28","first-page":"373","article-title":"Declaration of Helsinki world medical association declaration of Helsinki","volume":"79","year":"2013","journal-title":"Bull. World Health Organ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies","volume":"12","author":"Elm E","year":"2014","journal-title":"Int. J. Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1002\/art.23916","article-title":"Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis","volume":"59","author":"Magni-Manzoni","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B32","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J. Rheumatol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","article-title":"Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis","volume":"59","author":"Tibaldi","year":"2019","journal-title":"Rheumatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-na\u00efve patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res. Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/rheumatology\/key262","article-title":"Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","article-title":"Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment","volume":"5","author":"Yasin","year":"2018","journal-title":"Curr. Opin. Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5114\/ceji.2019.87066","article-title":"Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab","volume":"44","author":"Vilaiyuk","year":"2019","journal-title":"Cent. Eur. J. Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1136\/annrheumdis-2018-eular.6487","article-title":"AB0431 earlier age at therapy initiation is associated with better response to tocilizumab therapy in patients with juvenile idiopathic polyarthritis","volume":"77","author":"Alexeeva","year":"2018","journal-title":"Ann. Rheum. Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.665028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T04:58:36Z","timestamp":1620622716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.665028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":40,"alternative-id":["10.3389\/fmed.2021.665028"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.665028","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"article-number":"665028"}}